RegenBio Care
Your Health. Our Science.
Start Today
Regenerative Research

Peer-reviewed science,
curated for clinicians and patients.

Peer-reviewed scientific literature on MSC exosome research, sourced from PubMed and the National Center for Biotechnology Information (NCBI).

248
studies catalogued
25
conditions covered
100%
peer-reviewed
PubMed
verified citations

Browse by condition.

Research search

Ask Dr./Detective Sherlock Holmes to help.

Your Healthcare Detective and Healthcare Advocate. We pass your query to Google Scholar with an MSC-exosome prefix so the results are scoped to the literature you care about.

Seed studies

10 cited
  • COVID·Stem Cells and Development·2020

    Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19

    Sengupta et al.

    24 patients with severe COVID-19 ARDS received a single IV dose of bone marrow MSC-derived exosomes (ExoFlo). 83% survival rate, significant reduction in inflammatory markers (CRP, ferritin, D-dimer), and improvement in oxygenation within 72 hours.

    Read on PubMed
  • COVID·Stem Cell Research & Therapy·2022·NCT04276987 (MEXCOVID)

    Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19

    Zhu et al.

    7 patients with severe COVID-19 pneumonia received 5 consecutive daily nebulized doses of haMSC-Exos. Well tolerated, no adverse events, with CT imaging improvement of pulmonary lesions in 4 of 7 patients within 7 days.

    Read on PubMed
  • COVID·Stem Cell Reviews and Reports·2022·ChiCTR2000030261

    Nebulization Therapy with Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for COVID-19 Pneumonia

    Chu et al.

    Nebulized UCMSC-derived exosomes were safe (no acute or secondary allergic reactions), promoted pulmonary lesion absorption, and reduced hospitalization duration in mild COVID-19 cases. Authors recommend earliest-possible administration for maximum benefit.

    Read on PubMed
  • COVID·CHEST·2023

    Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicle Infusion for the Treatment of Respiratory Failure From COVID-19: A Randomized, Placebo-Controlled Dosing Clinical Trial

    Lightner et al.

    Phase II randomized placebo-controlled trial of two IV doses of BM-MSC EVs in COVID-19 respiratory failure. Demonstrated feasibility of large-scale clinical-grade MSC-EV production and excellent clinical tolerance.

    Read on PubMed
  • Autoimmune·Frontiers in Immunology·2021

    Effects of Mesenchymal Stem Cell-Derived Exosomes on Autoimmune Diseases

    Shen et al.

    Substantial therapeutic progress documented across multiple sclerosis (MS), systemic lupus erythematosus (SLE), type-1 diabetes (T1DM), uveitis, rheumatoid arthritis (RA), and inflammatory bowel disease (IBD). MSC-exosomes show clear inhibitory effects on innate and adaptive immune effector cells.

    Read on PubMed
  • Autoimmune·BMC Ophthalmology·2025·IRCT20211102052948N1

    Efficacy of topical mesenchymal stem cell exosome in Sjögren's syndrome-related dry eye: a randomized clinical trial

    Hoseini et al.

    Triple-blinded RCT of topical MSC-derived exosome eye drops (10 µg twice daily for 2 weeks) vs PBS control in Sjögren's syndrome dry eye. Demonstrated safety and substantial therapeutic potential vs current insufficient standard treatments.

    Read on PubMed
  • Autoimmune·Biomolecules·2024

    Mesenchymal Stem Cell-Derived Exosomes: Emerging as a Promising Cell-Free Therapeutic Strategy for Autoimmune Hepatitis

    Wu et al.

    MSC-Exos demonstrate anti-inflammatory and anti-fibrotic properties while promoting liver regeneration in autoimmune hepatitis models. Currently limited treatment options exist for advanced AIH that can progress to cirrhosis.

    Read on PubMed
  • Alzheimer's & Dementia·BMJ Open·2023·NCT04388982 (Ruijin Hospital, Shanghai)Headline study

    Clinical safety and efficacy of allogenic human adipose mesenchymal stromal cells-derived exosomes in patients with mild to moderate Alzheimer's disease: a phase I/II clinical trial

    Xie et al.

    First-in-human MSC-Exo AD trial. Patients received intranasal allogenic adipose MSC-exosomes twice weekly for 12 weeks. In the medium-dose arm, ADAS-cog scores decreased by 2.33 points (cognitive improvement) and MoCA scores increased by 2.38 points at week 12 vs baseline. No adverse events reported.

    Read on PubMed
  • Alzheimer's & Dementia·Pharmaceuticals·2023

    Mesenchymal and Neural Stem Cell-Derived Exosomes in Treating Alzheimer's Disease

    Wei et al.

    Systematic review documenting that MSC-derived exosomes improved AD-like behaviors including impaired learning and memory across multiple preclinical models, and reduced Aβ42-induced neurotoxicity in AD cell culture models.

    Read on PubMed
  • Alzheimer's & Dementia·Brain and Behavior·2025

    Therapeutic and Diagnostic Roles of MSC-Derived Exosomes in Alzheimer's Disease

    Patil et al.

    Comprehensive review of intranasal MSC-Exo delivery for AD, including the Ruijin Hospital Phase I/II trial (NCT04388982) and a large-scale US-registered trial planning enrollment of up to 5000 patients to evaluate MSC therapy safety and efficacy.

    Read on PubMed

Citations are for educational reference only and do not constitute medical advice. Discuss relevance to your care with your physician.

Clinical trials

Active and planned clinical trials.

RegenBio Care partners with research-grade clinical programs to advance the evidence base for regenerative care in chronic recovery. Below are programs currently enrolling or in late-stage planning.

Many of our care protocols are part of structured clinical research programs. Your physician will discuss eligibility and informed consent during your consultation.

Enrolling SoonSan Diego, CA

RegenBio Care Long COVID-19 Trial

Express Interest
Indication

Long COVID / Post-Acute Sequelae of SARS-CoV-2 (PASC)

Therapy class

MSC-derived exosome program

Planned launch: Within 2–3 weeks of May 2026
Why this matters

Long COVID affects roughly 1 in 5 adults who had COVID-19 with significant limitations in daily activity (CDC), and ~6 in 100 develop post-COVID-19 condition (WHO). Evidence base for MSC-exosome therapy in COVID-associated pulmonary and inflammatory pathology continues to expand — see Sengupta et al. (2020), Zhu et al. (2022), Lightner et al. (2023, CHEST).

Eligibility, protocol, and IRB details forthcoming.

Or schedule a screening call:

ZoomGoogle Meet
Planning StageTBD

Alzheimer's & Mild Cognitive Decline Program

Join Interest List
Indication

Mild to moderate Alzheimer's disease, MCI

Therapy class

Intranasal MSC-Exo protocol (model: NCT04388982 / Ruijin Hospital)

Why this matters

Xie et al. (2023, BMJ Open) Phase I/II trial demonstrated cognitive improvement (ADAS-cog −2.33, MoCA +2.38 in medium-dose arm) with intranasal MSC-exosome administration over 12 weeks. No adverse events reported. RegenBio Care is structuring a US-based protocol building on this evidence base.

Evidence basis

Xie et al. (2023) Phase I/II — first-in-human MSC-Exo AD trial. Patil et al. (2025) reviews subsequent US-registered protocols planning up to 5,000 patient enrollment.

Or schedule a screening call:

ZoomGoogle Meet
Planning StageIn development

Additional Research Programs

Get Notified
Indication

Autoimmune recovery, POTS/dysautonomia, neuroimmune dysfunction

Therapy class

Multiple protocols, indication-specific

Why this matters

Additional programs in development for autoimmune recovery, POTS/dysautonomia, and neuroimmune dysfunction. Contact us to join the early-access list.

Or schedule a screening call:

ZoomGoogle Meet
One last thing

Ready to start your care journey?

Schedule a free 15-minute consultation with a RegenBio Care physician advisor. Zoom or Google Meet — your pick.

Schedule with ZoomSchedule with Google Meet